IO-106
Immune-Onc is evaluating IO-106, an antagonist antibody targeting LAIR1, an immune inhibitory receptor. The company’s preclinical research supports the proposed mechanisms of action of IO-106 and its evaluation as a potential treatment for solid tumors.
About LAIR1
Researchers have shown that expression of the inhibitory receptor Leukocyte‐Associated Immunoglobulin‐Like Receptor 1 (LAIR1) correlates with worse survival in several cancers. Studies suggest that binding of LAIR1 to its ligand collagen leads to T-cell suppression and exhaustion, as well as dendritic cell deactivation in the tumor microenvironment.
About IO-106
IO-106 is a first-in-class monoclonal antibody that antagonizes LAIR1. It has broad potential in collagen-rich solid tumors and could be a candidate for combination therapy with anti-PD-(L)1 or other immunotherapies. Preclinical research shows that IO-106 can reverse collagen-mediated immune suppression and mobilize anti-tumor immunity of multiple cell types including lymphocytes and myeloid cells.